| Sumario: | Immunohistochemistry Critical Assay Performance Controls (iCAPC) are gold standard sets of tissue controls that robustly show strong, weak and negative expression for specified proteins, initially introduced to provide standardization and reduction of pre-analytical and analytical errors of the respective immunohistochemistry (IHC) stains. Within Vancouver Coastal Health, iCAPC are incorporated for all class II antibodies including BRAF V600E. BRAF is a predictive and prognostic biomarker for cancers such as colorectal adenocarcinoma and metastatic melanoma. BRAF V600E protein detection by IHC is comparable to the gold standard polymerase chain reaction (PCR) assay. An exhaustive review yielded no previous studies evaluating the efficacy of iCAPC in reducing inter-observer interpretation variability. In this study, 173 cases with reported BRAF mutational status were collected, providing two sets of slides: routine controls (115) and iCAPC (58). One pathology resident interpreted the two slide sets. Kappa coefficients for the pathology resident's results to the previous reports were calculated: Based on this preliminary data, the use of BRAF V600E iCAPC decreases inter-observer interpretation variability. Five additional residents will review the two slide sets, with an additional 56 slides in the iCAPC set.
|
|---|